Theramex And Alkem’s Enzene Ally On Denosumab

Women’s Health Firm Gains Rights To Prolia Biosimilar In Europe And Australia

 
• By Dave Wallace

Women’s health specialist Theramex has struck a deal with Alkem’s Enzene Biosciences biotech subsidiary to gain rights to Enzene’s proposed denosumab biosimilar version of Prolia in Europe and Australia.

Prolia Pack Amgen Injector
Theramex has gained rights to Enzene’s Prolia rival • Source: Alamy

More from Deals

More from Business